Published in J Neuroimmunol on May 01, 2007
Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev (2011) 1.66
Pharmacological characterization of LPS and opioid interactions at the toll-like receptor 4. Br J Pharmacol (2013) 0.99
Beta-funaltrexamine inhibits inducible nitric-oxide synthase expression in human astroglial cells. J Neuroimmune Pharmacol (2008) 0.84
Dual regulation of mu opioid receptors in SK-N-SH neuroblastoma cells by morphine and interleukin-1β: evidence for opioid-immune crosstalk. J Neuroimmunol (2010) 0.81
The opioid antagonist, β-funaltrexamine, inhibits NF-κB signaling and chemokine expression in human astrocytes and in mice. Eur J Pharmacol (2015) 0.80
Chronic inorganic mercury exposure induces sex-specific changes in central TNFα expression: importance in autism? Neurosci Lett (2011) 0.78
α-Synuclein potentiates interleukin-1β-induced CXCL10 expression in human A172 astrocytoma cells. Neurosci Lett (2011) 0.78
Neuromelanin inhibits CXCL10 expression in human astroglial cells. Neurosci Lett (2010) 0.78
Β-funaltrexamine inhibits chemokine (CXCL10) expression in normal human astrocytes. Neurochem Int (2013) 0.76
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res (1987) 10.80
Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature (1985) 9.18
Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med (1993) 4.94
Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae. J Biol Chem (1996) 3.54
Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther (2003) 3.29
CXC chemokines in angiogenesis. J Leukoc Biol (2000) 3.17
Inhibition of astroglial nuclear factor kappaB reduces inflammation and improves functional recovery after spinal cord injury. J Exp Med (2005) 2.51
Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther (2000) 2.14
The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-kappaB by directly targeting p65. J Biol Chem (1998) 1.99
Synergistic increases in intracellular Ca2+, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat. Glia (2005) 1.86
Mechanisms of the blood-brain barrier disruption in HIV-1 infection. Cell Mol Neurobiol (2005) 1.81
The role of nuclear factor kappaB in tumor necrosis factor-regulated transcription of the human mu-opioid receptor gene. Mol Pharmacol (2003) 1.73
Induction of nitric-oxide synthase and activation of NF-kappaB by interleukin-12 p40 in microglial cells. J Biol Chem (2000) 1.70
Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J Neurochem (2002) 1.63
Identification of a T cell chemotactic factor in the cerebrospinal fluid of HIV-1-infected individuals as interferon-gamma inducible protein 10. J Neuroimmunol (1999) 1.53
HIV-1 Tat and opiate-induced changes in astrocytes promote chemotaxis of microglia through the expression of MCP-1 and alternative chemokines. Glia (2006) 1.53
The role of neuroinflammation in neuropathic pain: mechanisms and therapeutic targets. Drug Discov Today (2006) 1.49
Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol (2005) 1.49
Reducing inflammation decreases secondary degeneration and functional deficit after spinal cord injury. Exp Neurol (2003) 1.35
Regulation of chemokine receptor expression in human microglia and astrocytes. J Neuroimmunol (2003) 1.31
Opioid-induced preconditioning: recent advances and future perspectives. Vascul Pharmacol (2005) 1.30
Primary astroglial cultures derived from several rat brain regions differentially express mu, delta and kappa opioid receptor mRNA. Brain Res Mol Brain Res (1995) 1.29
Prolonged expression of interferon-inducible protein-10 in ischemic cortex after permanent occlusion of the middle cerebral artery in rat. J Neurochem (1998) 1.27
Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer's disease. J Neuroimmunol (2000) 1.27
Opioid and opiate immunoregulatory processes. Crit Rev Immunol (1996) 1.19
Regional, developmental, and cell cycle-dependent differences in mu, delta, and kappa-opioid receptor expression among cultured mouse astrocytes. Glia (1998) 1.14
Hyperbaric oxygen therapy reduces neuroinflammation and expression of matrix metalloproteinase-9 in the rat model of traumatic brain injury. Neuropathol Appl Neurobiol (2006) 1.12
Macrophage-induced inflammation affects hippocampal plasticity and neuronal development in a murine model of HIV-1 encephalitis. Glia (2005) 1.12
Morphine modulates chemokine gene regulation in normal human astrocytes. Clin Immunol (2005) 1.09
Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases. Neurotox Res (2005) 1.09
Morphine regulates gene expression of alpha- and beta-chemokines and their receptors on astroglial cells via the opioid mu receptor. J Immunol (2002) 1.08
Inhibition by naloxone stereoisomers of beta-amyloid peptide (1-42)-induced superoxide production in microglia and degeneration of cortical and mesencephalic neurons. J Pharmacol Exp Ther (2002) 1.07
Inhibition of tumor necrosis factor-alpha-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats. Mol Pharmacol (2004) 1.06
Neuroprotection in ischemia-reperfusion injury: an antiinflammatory approach using a novel broad-spectrum chemokine inhibitor. J Cereb Blood Flow Metab (2001) 1.04
Ethanol-induced modulation of inducible nitric-oxide synthase activity in human A172 astrocytoma cells. Alcohol Clin Exp Res (2002) 1.01
Identification and molecular characterization of rat CXCR3: receptor expression and interferon-inducible protein-10 binding are increased in focal stroke. Mol Pharmacol (2000) 1.01
Preferential vulnerability of astroglia and glial precursors to combined opioid and HIV-1 Tat exposure in vitro. Eur J Neurosci (2004) 0.98
Transcriptional regulation of the human mu-opioid receptor gene by interleukin-6. Mol Pharmacol (2004) 0.98
Neutralization of the chemokine CXCL10 enhances tissue sparing and angiogenesis following spinal cord injury. J Neurosci Res (2004) 0.97
Expression of mRNAs of multiple growth factors and receptors by neuronal cell lines: detection with RT-PCR. Neurochem Res (1995) 0.94
Morphine prevents glutamate-induced death of primary rat neonatal astrocytes through modulation of intracellular redox. Immunopharmacol Immunotoxicol (2004) 0.93
Ethanol increases nuclear factor-kappa B activity in human astroglial cells. Neurosci Lett (2004) 0.93
Targeting the chemokine receptor CXCR3 and its ligand CXCL10 in the central nervous system: potential therapy for inflammatory demyelinating disease? Curr Neurovasc Res (2004) 0.88
Morphine modulation of the ubiquitin-proteasome complex is neuroprotective. Med Sci Monit (2005) 0.87
Induction of hypoxia inducible factor-1 attenuates metabolic insults induced by 3-nitropropionic acid in rat C6 glioma cells. J Neurochem (2005) 0.86
Acute ethanol exposure modulates expression of inducible nitric-oxide synthase in human astroglia: evidence for a transcriptional mechanism. Alcohol (2004) 0.86
Interferon-beta-1-b (IFN-B) decreases induced nitric oxide (NO) production by a human astrocytoma cell line. J Neuroimmunol (1998) 0.86
Neuroprotection of naloxone against ischemic injury in rats: role of mu receptor antagonism. Neurosci Lett (2003) 0.85
Selective and interactive down-regulation of mu- and delta-opioid receptors in human neuroblastoma SK-N-SH cells. Mol Pharmacol (1993) 0.83
Regulation of serotonin transporter gene expression in human glial cells by growth factors. Eur J Pharmacol (2001) 0.83
Chronic ethanol inhibits CXC chemokine ligand 10 production in human A172 astroglia and astroglial-mediated leukocyte chemotaxis. Neurosci Lett (2004) 0.81
Design and synthesis of naltrexone-derived affinity labels with nonequilibrium opioid agonist and antagonist activities. Evidence for the existence of different mu receptor subtypes in different tissues. J Med Chem (1984) 0.80
Identification of cis-regulatory regions necessary for robust Nos2 promoter activity in glial cells: indirect role for NF-kappaB. J Neurochem (2003) 0.80
Antagonism of morphine-like discriminative effects by beta-funaltrexamine. Pharmacol Biochem Behav (1997) 0.76
Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 2.83
Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2004) 1.73
Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res (2004) 1.59
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg (2007) 1.54
Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol (2005) 1.53
Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg (2005) 1.49
Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resection. Am J Gastroenterol (2004) 1.43
Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys (2007) 1.28
Evaluation of internal lung motion for respiratory-gated radiotherapy using MRI: Part I--correlating internal lung motion with skin fiducial motion. Int J Radiat Oncol Biol Phys (2004) 1.23
Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung. Int J Radiat Oncol Biol Phys (2012) 1.21
Radiation injury of the lung after three-dimensional conformal radiation therapy. AJR Am J Roentgenol (2002) 1.18
Accumulation of the common mitochondrial DNA deletion induced by ionizing radiation. FEBS Lett (2004) 1.13
Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2003) 1.12
A deformable-model approach to semi-automatic segmentation of CT images demonstrated by application to the spinal canal. Med Phys (2004) 1.08
Semiautomated four-dimensional computed tomography segmentation using deformable models. Med Phys (2005) 1.06
Volumetric modulated arc planning for lung stereotactic body radiotherapy using conventional and unflattened photon beams: a dosimetric comparison with 3D technique. Radiat Oncol (2011) 1.05
Correlation of gross tumor volume excursion with potential benefits of respiratory gating. Int J Radiat Oncol Biol Phys (2004) 1.04
Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys (2003) 1.03
Imaging of the patient with non-small cell lung cancer. Radiology (2005) 0.99
Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys (2005) 0.97
Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMRT) to the chest. Cancer J (2004) 0.96
Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys (2004) 0.95
Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. J Thorac Cardiovasc Surg (2005) 0.94
Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. Int J Radiat Oncol Biol Phys (2003) 0.92
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys (2004) 0.91
Assessment of lung tumor motion and setup uncertainties using implanted fiducials. Int J Radiat Oncol Biol Phys (2007) 0.91
Assessment of tissue oxygen tension: comparison of dynamic fluorescence quenching and polarographic electrode technique. Crit Care (2002) 0.90
Characterization of mu, kappa, and delta opioid binding in amphibian whole brain tissue homogenates. J Pharmacol Exp Ther (2002) 0.90
Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys (2004) 0.89
Intensity-modulated radiation therapy for mesothelioma: impact of multileaf collimator leaf width and pencil beam size on planning quality and delivery efficiency. Int J Radiat Oncol Biol Phys (2005) 0.88
Functional lung imaging in thoracic cancer radiotherapy. Cancer Control (2008) 0.87
Evaluation of internal lung motion for respiratory-gated radiotherapy using MRI: Part II-margin reduction of internal target volume. Int J Radiat Oncol Biol Phys (2004) 0.87
Predicting response to clinical radiotherapy: past, present, and future directions. Cancer Control (2008) 0.86
Beta-funaltrexamine inhibits inducible nitric-oxide synthase expression in human astroglial cells. J Neuroimmune Pharmacol (2008) 0.84
Radiation injury to the liver after intensity-modulated radiation therapy in patients with mesothelioma: an unusual CT appearance. AJR Am J Roentgenol (2005) 0.84
Dosimetric benefits of respiratory gating: a preliminary study. J Appl Clin Med Phys (2004) 0.84
Treatment planning for lung cancer: traditional homogeneous point-dose prescription compared with heterogeneity-corrected dose-volume prescription. Int J Radiat Oncol Biol Phys (2003) 0.84
Dual regulation of mu opioid receptors in SK-N-SH neuroblastoma cells by morphine and interleukin-1β: evidence for opioid-immune crosstalk. J Neuroimmunol (2010) 0.81
Target definition and contouring in carcinoma of the lung and esophagus. Rays (2004) 0.80
Systemic and spinal administration of the mu opioid, remifentanil, produces antinociception in amphibians. Eur J Pharmacol (2006) 0.79
Chronic inorganic mercury exposure induces sex-specific changes in central TNFα expression: importance in autism? Neurosci Lett (2011) 0.78
Effects of quantum noise in 4D-CT on deformable image registration and derived ventilation data. Phys Med Biol (2013) 0.78
α-Synuclein potentiates interleukin-1β-induced CXCL10 expression in human A172 astrocytoma cells. Neurosci Lett (2011) 0.78
Predicting radiosensitivity using DNA end-binding complex analysis. Clin Cancer Res (2004) 0.78
Neuromelanin inhibits CXCL10 expression in human astroglial cells. Neurosci Lett (2010) 0.78
Compensator-based intensity-modulated radiation therapy for malignant pleural mesothelioma post extrapleural pneumonectomy. J Appl Clin Med Phys (2008) 0.77
A pharmacological comparison of the cloned frog and human mu opioid receptors reveals differences in opioid affinity and function. Eur J Pharmacol (2008) 0.77
Quality assurance evaluation of delivery of respiratory-gated treatments. J Appl Clin Med Phys (2004) 0.77
DNA-PK and ATM are required for radiation-enhanced integration. Radiat Res (2002) 0.77
Tumor oxygenation and acidification are increased in melanoma xenografts after exposure to hyperglycemia and meta-iodo-benzylguanidine. Radiat Res (2003) 0.77
Outcomes and patterns of failure in bronchial carcinoid tumors. Int J Radiat Oncol Biol Phys (2003) 0.77
High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clin Cancer Res (2005) 0.76
Radiosensitivity is predicted by DNA end-binding complex density, but not by nuclear levels of band components. Radiother Oncol (2004) 0.76
Β-funaltrexamine inhibits chemokine (CXCL10) expression in normal human astrocytes. Neurochem Int (2013) 0.76
Evolution and faith: empathy is misplaced. Science (2008) 0.75
Uncertainties in physical and biological targeting with radiation therapy. Rays (2004) 0.75
Personalized treatment approaches in radiation oncology: the future is now. Cancer Control (2008) 0.75
Analysis of incidental radiation dose to uninvolved mediastinal/supraclavicular lymph nodes in patients with limited-stage small cell lung cancer treated without elective nodal irradiation. Med Dosim (2011) 0.75
Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus? Gastrointest Endosc (2009) 0.75